Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04033328
Title Study of ORIC-101 in Combination With Enzalutamide
Recruitment Active, not recruiting
Gender male
Phase Phase I
Variant Requirements No
Sponsors Oric Pharmaceuticals

prostate adenocarcinoma


Enzalutamide + ORIC-101

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.